• About
• Links
• Contact
• Sitemap

The World Schizophrenia Market 2005-2010

Table of Contents

• 1. Executive Summary
• 2. Introduction to Schizophrenia
  • 2.1 Symptoms of the Condition
  • 2.2 Diagnosis of Schizophrenia
  • 2.3 Links with Other Disorders
  • 2.4 Epidemiology of Schizophrenia
  • 2.5 Causes and Physiological Characteristics of Schizophrenia
  • 2.6 The Treatment of Schizophrenia by Drugs
  • 2.7 Other Aspects of Treating or Managing Schizophrenia
  • 2.8 Mechanisms of the Newer Therapeutic Agents - The Atypical Antipsychotics
  • 2.9 An Overview of How the Typical Antipsychotic Drugs Differ from the Atypical Antipsychotics
  • 2.10 Adherence by Schizophrenics is Often Low
  • 2.11 Off-Label Prescription Extending Approved Indications for Atypical Antipsychotic Drugs
  • 2.12 The Prospects for Patients
• 3. The World Market 2003-2004 for Anti-Schizophrenic Drugs
  • 3.1 The Market for Treating Schizophrenia Contains Three Major Blockbusters
  • 3.2. Eli Lilly's Zyprexa Led the Schizophrenia Market in 2004
  • 3.3 The Other Atypical Antipsychotics Displayed Healthy Revenues in 2004
    • 3.3.1 Johnson & Johnson's Risperdal - Second Largest Revenue Generator in Market
    • 3.3.2 AstraZeneca's Seroquel - Maintaining a Strong Position
    • 3.3.3 Otsuka Pharmaceutical & Bristol-Myers Squibb's Abilify Shows Enormous Potential
    • 3.3.4 Pfizer's Geodon - A Promising Start
    • 3.3.5 Novartis' Clozaril/Leponex - The Pioneering Atypical Antipsychotic
  • 3.4 The Atypical Antipsychotic Drugs Still Suffer from Concerns Over Side Effects
  • 3.5 Patent Expiry Among the Leading Schizophrenia Drugs - An Increasing Threat 2005-2010
  • 3.6 Comparative Studies on Schizophrenia Drugs - a Blessing or a Curse for the Market Leaders?
• 4. An Analysis of Factors that Influence the Schizophrenia Market
  • 4.1 SWOT Analysis of the Schizophrenia Market?
  • 4.2 What Are the Main Drivers, Strengths and Opportunities in the Schizophrenia Market?
  • 4.3 Principal Drivers in the Schizophrenia Market
  • 4.4 The Atypical Antipsychotics Constitute a Large, High-Growth Market
  • 4.5 Maintaining High Revenue Generation in Spite of Challenges
  • 4.6 There is Scope for Greater Penetration into Related Markets
  • 4.7 Advances in Technology Likely to Bring Benefits to the Market
  • 4.8 Comparative Studies - a Two Edged Sword
  • 4.9 The Principal Restraints in the Schizophrenia Market
  • 4.10 Risk of Diabetes and Other Serious Side Effects with the Atypical Antipsychotic Drugs
  • 4.11 Concerns Over the High Price of the Treatments - Who Yields the Power?
  • 4.12 A Discussion of Generic Drugs in This Market - How Great is Their Threat?
• 5. The World Market for Schizophrenia Treatments 2004-2010
  • 5.1 World Revenue from 2004 to 2010 - A Maturing Market with High Revenue Potential
  • 5.2 Zyprexa to Retain Market Leadership Despite Pressures
  • 5.3 Risperdal - Strong Revenue Potential Despite Side Effects and Generics Threat
  • 5.4 Will Seroquel Remain a Strong Contender?
  • 5.5 Can Abilify Build upon Early Promise?
  • 5.6 Geodon has Growth Potential Despite Generics Threat
  • 5.7 Can Clozaril ''Re-Invent'' Itself to Offset Decline?
• 6. A Geographical Breakdown of the World Market
  • 6.1 Schizophrenia - A World Market Led by US Sales
  • 6.2 The US Leads the World in Healthcare Spending
  • 6.3 The US and Europe are the Most Important Markets for Schizophrenia Treatments
• 7. An Analysis of Unmet Needs in the Schizophrenia Market
  • 7.1 Analysing Efficacy, Safety and Tolerability in the Schizophrenia Market via Perceptual Mapping
  • 7.2 How Much Scope is There to Improve Efficacy in Schizophrenia Drugs?
  • 7.3 How Much Scope is There to Improve Safety and Tolerability in Schizophrenia Drugs?
  • 7.4 Pricing of the Atypical Antipsychotics - Close Scrutiny by Medical Authorities and Concern Amongst Patients' Groups
  • 7.5 Screening and Diagnosis by Healthcare Services is a Necessary Prerequisite for Market Growth
  • 7.6 Direct Advertising - An Opportunity to Educate Consumers but also a Source of Controversy
• 8. Pipeline Drugs for Schizophrenia
  • 8.1 Agents in Preclinical Development
    • 8.1.1 BL-1020
    • 8.1.2 Other Agents in Preclinical Development
  • 8.2 Agents in Phase I of Clinical Development
    • 8.2.1 TC-1827
    • 8.2.2 Other Agents in Phase I Clinical Development
  • 8.3 Agents in Phase II of Clinical Development
    • 8.3.1 Talnetant
    • 8.3.2 SM13496 (Lurasidone)
    • 8.3.3 ACP-103
    • 8.3.4 ACP-104
    • 8.3.5 Org 24448
    • 8.3.6 Other Agents in Phase II Clinical Development
  • 8.4 Agents in Phase III of Clinical Development
    • 8.4.1 Iloperidone
    • 8.4.2 Asenapine
    • 8.4.3 Bifeprunox
    • 8.4.4 Blonanserin
    • 8.4.5 Paliperidone
    • 8.4.6 Osanetant
    • 8.4.7 Other Agents in Phase III Clinical Development
  • 8.5 Treatments Recently Approved for Treating Schizophrenia
    • 8.5.1 Serdolect
  • 8.6 The Further Development of Existing Treatments for Schizophrenia
    • 8.6.1 A Line Extension of AstraZeneca's Seroquel
  • 8.7 An Overall Assessment of Pipeline Developments for the Schizophrenia Market
• 9 Conclusions of this Market Study

Tables Included in this Report

Table 1.1 Market Leading Drugs for Treating Schizophrenia

Table 2.1 First Generation Antipsychotic Drugs for Treating Schizophrenia (the Typical Antipsychotics)

Table 2.2 Mild and Serious Side Effects of First Generation Antipsychotics

Table 2.3 Second Generation Antipsychotic Drugs for Treating Schizophrenia (the Atypical Antipsychotics)

Table 2.4 Mild and Serious Side Effects of Second Generation Antipsychotics

Table 3.1 Best-Selling Drugs in the Therapeutic Category Psychotherapeutic Agents in 2004

Table 3.2 The Leading Drugs for Treating Schizophrenia: Indications and Modes of Action

Table 3.3 The Leading Drugs for Treating Schizophrenia: 2004 Revenues and Growth Rates

Table 3.4 Market Shares for the Leading Schizophrenia Drugs in 2004

Table 3.5 Side Effects and Potential Risks Associated with Leading Drugs for Schizophrenia

Table 3.6 Patent Expiry in the Market Leading Drugs for Schizophrenia

Table 4.1 Side Effect Profiles of the Second Generation Antipsychotic Drugs

Table 5.1 World Revenues ($m) for the Leading Schizophrenia Drugs 2004 to 2010

Table 5.2 Compound Annual Growth Rates (CAGRs) for the Leading Schizophrenia Drugs

Table 5.3 World Revenues ($m) of Seroquel and Abilify Only, 2004-2010

Table 5.4 World Revenues for Schizophrenia Treatments, 2004 and 2010 Compared

Table 5.5 Market Share (%) for Schizophrenia Drugs, 2004 and 2010 Compared

Table 6.1 A Global Breakdown of the Schizophrenia Market by Country and Region, 2004

Table 6.2 Total Health Spending ($) and Drug Expenditure per Patient in Major Countries in 2002

Table 6.3 Annual Average Growth Rates (%) in GDP, Total and Public Health Expenditure of Principal Countries, 1997-2002

Table 7.1 Efficacy and Side Effect Profiles of the Leading Schizophrenia Drugs

Table 7.2 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy

Table 7.3 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy (continued)

Table 7.4 Direct to Consumer Advertising (DTC) Expenditure in the Schizophrenia Market

Table 8.1 Pre-clinical Development

Table 8.2 Phase I Clinical Trials

Table 8.3 Phase II Clinical Trials

Table 8.4 Phase III Clinical Trials

Table 8.5 Line Extensions and Extended Approval for Some of the Leading Drugs (July 2005)

Table 9.1 The Relative Strengths and Weaknesses of the Leading Schizophrenia Drugs with a Prediction of their Future Sales Potential

Figures Included in this Report

Figure 3.1 Sales of Leading Psychotherapeutic Agents in 2004 by Main Indication

Figure 3.2 Revenues from the Leading Schizophrenia Drugs in 2004

Figure 3.3 Percentage Growth in Revenues from 2003-2004 for the Leading Drugs

Figure 3.4 Percentage Market Shares for the Leading Drugs for Schizophrenia in 2004

Figure 4.1 A SWOT Chart for the Schizophrenia Market

Figure 5.1 Total World Revenues ($m) for Schizophrenia Treatments 2004-2010

Figure 5.2 Growth Rates (%) for Schizophrenia Treatments 2004-2010

Figure 5.3 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010

Figure 5.4 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010

Figure 5.5 World Revenues ($m) for Schizophrenia Treatments 2004 and 2010 Compared

Figure 5.6 Change in World Revenue ($m), 2004 and 2010 Compared

Figure 5.7 World Market Share for the Leading Drugs in 2004

Figure 5.8 World Market Share for the Leading Drugs in 2010

Figure 5.9 World Market Share 2004 compared with 2010

Figure 5.10 Change in World Market (%) Share 2004 to 2010

Figure 5.11 World Growth Rate for Zyprexa 2004-2010

Figure 5.12 World Growth Rate for Risperdal 2004-2010

Figure 5.13 World Growth Rate for Seroquel 2004-2010

Figure 5.14 World Growth Rate for Abilify 2004-2010

Figure 5.15 World Growth Rate for Geodon 2004-2010

Figure 5.16 World Growth Rate for Clozaril 2004-2010

Figure 6.1 Market Share (%) for Schizophrenia by Country and Region

Figure 6.2 Revenues ($m) for Schizophrenia by Country and Region

Figure 7.1 A Comparison of the Atypical Antipsychotics via Perceptual Mapping

Other users found this report page using the following search terms: Schizophrenia psychiatric antipsychotics psychosis market schizophrenia share treating drugs evolution global sm13496 serdolect novartisclozaril

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.